June 23, 2017 03:42 PM Eastern Daylight Time

BUSINESS WIRE

L'Imraldi® (adalimumab) de Samsung Bioepis est recommandé pour approbation par l'Agence européenne des médicaments

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Opens in new window

Download

Full Size JPEG, 5616x3744, 3.5 MB
Small JPEG, 480x320, 79.3 KB
Preview JPEG, 144x96, 17.5 KB
Thumbnail JPEG, 72x48, 9.8 KB

Smart Multimedia Gallery

Samsung Bioepis headquarters in Incheon, Korea. (Photo: Business Wire)

Samsung Bioepis headquarters in Incheon, Korea. (Photo: Business Wire)

View and Share Photo

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

View and Share Photo

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineer at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineers at the Samsung Bioepis R&D Center. (Photo: Business Wire)

Engineers at the Samsung Bioepis R&D Center. (Photo: Business Wire)

View and Share Photo

http://www.businesswire.it/multimedia/it/20170623005624/fr/4106078/

View and Share Logo

Share

Email

All News | News with Multimedia > Press Release: L'Imraldi® (adalimumab) de Samsung Bioepis est ...